A Director at XBiotech (NASDAQ: XBIT) is Selling Shares

By Carrie Williams

Yesterday, a Director at XBiotech (XBITResearch Report), Thorpe McKenzie, sold shares of XBIT for $6.86M.

This is McKenzie’s first Sell trade following 7 Buy transactions.

See today’s analyst top recommended stocks >>

Based on XBiotech’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $10.55 million and GAAP net loss of -$2,526,000. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $6.15 million. The company has a one-year high of $26.40 and a one-year low of $8.72. Currently, XBiotech has an average volume of 322.82K.

The insider sentiment on XBiotech has been neutral according to 17 insider trades in the past three months. This sentiment is slightly lower than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

XBiotech, Inc. is a biopharmaceutical company, which engages in development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. Its product pipeline include oncology, infectious diseases, dermatology, and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.